Oranair Plus

Bronchospasm in patients suffering from COPD who require regular treatment w/ both ipratropium & salbutamol.

Adult including elderly & childn >12 yr 1 single dose tid or qid.

Hypersensitivity to ipratropium Br, salbutamol sulfate or atropine or its derivatives. Patients w/ hypertrophic obstructive cardiomyopathy or tachyarrhythmia.

Risk of immediate hypersensitivity reactions after administration; paradoxical bronchospasm; potentially serious hypokalaemia. Patients must be instructed in the correct use of salbutamol + ipratropium & warned not to allow the soln or mist to enter the eyes especially in patients who may be pre-disposed to glaucoma. Should only be used after careful risk/benefit assessment in insufficiently controlled DM, recent MI &/or severe organic heart or vascular disorders, hyperthyroidism, pheochromocytoma, risk of narrow-angle glaucoma, prostatic hypertrophy or bladder-neck obstruction. Patients w/ underlying severe heart disease (eg, ischaemic heart disease, arrhythmia or severe heart failure) should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Patients w/ cystic fibrosis may be more prone to GI motility disturbances. Patient should be instructed to consult a doctor immediately in case of acute, rapidly worsening dyspnoea. Reports of lactic acidosis w/ high doses, mainly in patients w/ acute exacerbation of bronchospasm. May produce +ve results in tests for non-clinical substance abuse eg, doping test. Should not be used in pregnancy especially in 1st trimester. Not to be used during breast-feeding. No experience of use in childn <12 yr.

Headache, throat irritation, cough, dry mouth, GI motility disorders (including constipation, diarrhoea & vomiting), nausea, dizziness.

Not recommended w/ other anticholinergic drugs. Increased severity of side effects w/ β-mimetics, systemically absorbed anticholinergic & xanthine derivatives. Potentially serious reduction in effect w/ β-blockers. Enhanced effects w/ MAOIs or TCAs. Increased susceptibility to CV effects w/ halothane, trichloroethylene & enflurane.

Antiasthmatic & COPD Preparations

R03AL02 - salbutamol and ipratropium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.

Rx